Lenalidomide
Price | USD2500.00 |
Packge | 1KG |
- Min. Order:1KG
- Supply Ability:100KG
- Time:2019-07-06
Product Details
- Product NameLenalidomide
- CAS No.191732-72-6
- EINECS No.1308068-626-2
- MFC13H13N3O3
- MW259.26
- AppearancesolidWhite
- Melting point 265-268 °C
- storage temp. 2-8°C
- Boiling point 614.0±55.0 °C(Predicted)
- density 1.460±0.06 g/cm3(Predicted)
CR297
Product Name: | Lenalidomide |
Synonyms: | lenalidomide;3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione;LenalidomideLenalidomide;1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline;3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione;CC-5013;Revlimi;Lenalidomide(other anti-cancers) |
CAS: | 191732-72-6 |
MF: | C13H13N3O3 |
MW: | 259.26062 |
EINECS: | 1308068-626-2 |
Product Categories: | Molecular Targeted Antineoplastic;Intermediates & Fine Chemicals;Pharmaceuticals;Amines;Heterocycles;Inhibitor;CC-5013;Inhibitors;pharmaceutical intermediate |
Mol File: | 191732-72-6.mol |
Lenalidomide Chemical Properties |
Melting point | 269-271°C |
storage temp. | -20°C Freezer |
CAS DataBase Reference | 191732-72-6(CAS DataBase Reference) |
Lenalidomide Usage And Synthesis |
Antitumor Drug | Lenalidomide is a kind of antitumor drugs that developed by American biological pharmaceutical companies. Its chemical structure is similar with thalidomide. It has many functions such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of inflammatory cytokines, and increase the secretion of peripheral blood mononuclear anti-inflammatory cytokines. Vitro tests show that lenalidomide can inhibit the hyperplasia of some cell lines such as namalwa cell. It can inhibit the growth of patients’ multiple myeloma cells and MM1S cell. In addition, lenalidomide also can inhibit the expression of oxidase-2 (COX-2), but it has no effect on COX-1. Two multicenter randomized double-blind placebo-controlled clinical studies evaluate the safety and curative effect of lenalidomide that is used for multiple myeloma. The primary efficacy end point of the studies is time to progression (TTP). The interim analysis shows that TTP of the combination group is significantly superior to dexamethasone group. Recent clinical research results show that lenalidomide not only has curative effect on treating MDS and MM, but also on treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis and systemic bone marrow fibrosis disease with marrow unripe. Lenalidomide is a new derivative of thalidomide. But its teratogenic toxicity has not found. Its effectiveness is 100 times stronger than thalidomide. According to the result of three clinical trials, lenalidomide is the most effective drug in the treatment of multiple myeloma. More than half of patients can prolong survival time to more than 3 years after taking the drug. In addition, it is also the only effective drugs to treat myelodysplastic syndrome (MDS). Clinical results find that 64% of the patients with MDS need not use blood transfusion after treated by lenalidomide. In December 2005, the US Food and Drug Administration (FDA) approved lenalidomide to be used in the treatment of myelodysplastic syndrome (MDS). In March 2006, the FDA approved lenalidomide that was produced by American Celgene Biological Pharmaceutical Companies to be used in the treatment of multiple myeloma (MM). On September 23, 2011, the European Medicines Agency (EMA) released information that they have confirmed that the benefits of lenalidomide(trade name: Revlimid) to be used in the treatment of patients group that was approved outweighed the risks. Meanwhile they warned the doctor the risk of the drug to cause new cancer cases. Lenalidomide has been used with dexamethasone to treat adult patients with multiple myeloma that has received at least one treatment. Three new studies show that the incidence of new cancer will be increased in the patients with newly diagnosed multiple myeloma treated by lenalidomide and other combined treatment increased incidence of cancer. The above information is edited by the Chemicalbook Geqian. |
Chemical Properties | Yellow Solid |
Uses | Immunomodulatory drug; analog of Thalidomide. |
Uses | Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM. |
Uses | Lovastatin content <1% 98% |
Uses | A Thalidomide analog known to have immunomodulatory properties |
Definition | ChEBI: A dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha. |
Company Profile Introduction
Henan CoreyChem Co., Ltd, based on the original Zhengzhou Cote Chemical Research Institute, be brave in absorbing highly educated talents & overseas returnees; actively responded to Zhengzhou City High-tech Zone Government’s Special Care Policy, reorganized and founded in National University of Science and Technology Park, which is a high-tech, stock enterprise of high-end chemical Custom synthesis;The park was created by the People's Government of Henan Province, and proved by Ministry of Education and the National Science & Technology, taking the construction mode of "many college a park, and common development", mainly depends on Zhengzhou University and Henan University’s scientific research and talent advantage to set up Universities, scientific research institute and enterprise scientific research achievements transformation platform, to make high-tech enterprises incubate, is the new high-tech talent gathering base, high and new technology industry enterprise radiation base, colleges and universities technological innovation base.
Henan Coreychem Co., Ltd, facing global High-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and Rare chemicals trade. Corey have well-equipped machine, strong technical force and considerate marketing team service. We also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.
Recommended supplier
-
VIP1年
- Akums Lifesciences Ltd
- Lenalidomide 191732-72-6 99%
- Inquiry
- 2024-03-29
-
VIP1年
- Aspen Biopharma Labs Pvt Ltd
- Lenalidomide 98%
- Inquiry
- 2024-03-16
-
VIP1年
- Myosynth Laboratories Pvt Ltd
- 191732-72-6 Lenalidomide 98%
- Inquiry
- 2024-03-14
-
VIP1年
- Apicore Pharmaceuticals Pvt Ltd
- 191732-72-6 98%
- Inquiry
- 2024-03-07
-
VIP1年
- Mylan Laboratories Ltd
- 191732-72-6 Lenalidomide 98%
- Inquiry
- 2024-03-06
-
VIP1年
- Shreyaa Medilife Private Limited
- Lenalidomide 191732-72-6 98%
- Inquiry
- 2024-03-04
-
VIP1年
- Cohance Lifesciences (Previously RA Chem Pharma Ltd)
- 191732-72-6 98%
- Inquiry
- 2024-02-28
-
VIP1年
- Mac Chem Products (India) Pvt Ltd (Naprod Group)
- 191732-72-6 Lenalidomide 98%
- Inquiry
- 2024-02-28
-
VIP1年
- Beta Drugs
- Lenalidomide 191732-72-6 98%
- Inquiry
- 2024-02-26
-
VIP1年
- BDR Pharmaceuticals International Pvt Ltd
- Lenalidomide 98%
- Inquiry
- 2024-02-24
- Since:2014-12-17
- Address: No.967,15th Floor,Unit 7, Building 1, No.70 of DianChang Road, High-tech Development Zone, Zhengzho
INQUIRY